How a tumor grows can predict which cancer drug will work best
New research out of USC suggests the growth patterns specific to a tumor can predict which cancer therapies are likely to work best.
Nano LettersDOI: 10.1021/acs.nanolett.7b05292
(Reuters) - Celgene Corp announced a $9 billion cash buyout of Juno Therapeutics Inc on Monday as it moves to cement its position as a key player in a new range of cancer therapies.
(Wiley) Gene editing is one of the hottest topics in cancer research. A Chinese research team has now developed a gold-nanoparticle-based multifunctional vehicle to transport the 'gene scissors' to the tumor cell genome. As the authors report in the journal Angewandte Chemie, their nonviral transport and release platform of gene-editing systems has the additional advantage of combining hyperthermal cancer therapy with genetic modification.
(Ecole Polytechnique F é d é rale de Lausanne) Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.
This study revealed that the SALL4 ‐ KHDRBS3 network augments stemness through modulation of CD44 splicing in basal‐like breast cancer. This network enhances anoikis resistance for stemness. This study may contribute to the establishment of therapies targeting cancer stemness.
Authors: Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP Abstract Glioblastoma remains the most common, malignant primary cancer of the central nervous system with a low life expectancy and an overall survival of less than 1.5 years. The treatment options are limited and there is no cure. Moreover, almost all patients develop recurrent tumors, which typically are more aggressive. Therapeutically resistant glioblastoma or glioblastoma stem-like cells (GSCs) are hypothesized to cause this inevitable recurrence. Identifying prognost...
Authors: Kroemer G, Galluzzi L Abstract Despite considerable efforts from multiple laboratories worldwide, highly specific inhibitors of autophagy for clinical use are not yet available. Lysosomal inhibitors are being employed instead, in spite of multiple limitations that are summarized herein. PMID: 29348815 [PubMed]
This study aimed to evaluate trends in MSP use over time and the effect of MSPs on administration of postoperative chemotherapy.
Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TO...
This study proposes a two-dimensional (2D) oscillator model of p53 network, which is derived via reducing the multidimensional two-phase dynamics model into a model of ataxia telangiectasia mutated (ATM) and Wip1 variables, and studies the impact of p53-regulators on cell fate decision. First, the authors identify a 6D core oscillator module, then reduce this module into a 2D oscillator model while preserving the qualitative behaviours. The introduced 2D model is shown to be an excitable relaxation oscillator. This oscillator provides a mechanism that leads diverse modes underpinning cell fate, each corresponding to a cell...